SLC2A1 and neoplasm: In another study, an MRI contrast agent targeting GLUT1 for tumor detection was developed; this was constructed based on paramagnetic gadolinium oxide (Gd2O3), coated with polycyclodextrin (PCD), and further modified with glucose (Gd2O3@PCD-Glu) [93].